Literature DB >> 23661047

Late acute myopia syndrome induced by combination of sulfonamide drugs.

Pavel Kozner1, Katarina Simonova, Bretislav Brozek, Kuldev Singh.   

Abstract

We present a case of late acute myopia syndrome following discontinuation of treatment with a combination of sulphonamide drugs. To the best of our knowledge, this is the first reported case with such a presentation, and suggests that the pathophysiological basis for the acute myopia syndrome is a rapid decrease in serum carbonic anhydrase inhibitors levels which may lead to a rebound increase in the production of aqueous humor and accumulation of suprachoroidal fluid. It is further postulated that there may be a cumulative effect of sulphonamide drug use on carbonic anhydrase activity in the ciliary body epithelium of susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23661047     DOI: 10.1097/IJG.0b013e31829539f4

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  5 in total

1.  Comment on 'Topiramate maculopathy secondary to dose titration: first reported case'.

Authors:  P Kozner; S K Wagner; B Brozek; S Althauser
Journal:  Eye (Lond)       Date:  2015-10-16       Impact factor: 3.775

2.  Response to 'Comment on Topiramate maculopathy secondary to dose titration: first reported case'.

Authors:  R J Symes; P S Severn; R Rajendram; B Pal
Journal:  Eye (Lond)       Date:  2015-10-16       Impact factor: 3.775

Review 3.  A review of systemic medications that may modulate the risk of glaucoma.

Authors:  Annie Wu; Anthony P Khawaja; Louis R Pasquale; Joshua D Stein
Journal:  Eye (Lond)       Date:  2019-10-08       Impact factor: 3.775

4.  Topiramate-induced maculopathy in IgG4-related disease.

Authors:  Joanna DaCosta; Saad Younis
Journal:  Drug Healthc Patient Saf       Date:  2016-06-08

5.  Sumatriptan-induced angle-closure glaucoma: A case report.

Authors:  Cherng-Ru Hsu; Yi-Hao Chen; Ming-Cheng Tai; Da-Wen Lu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.